<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03355781</url>
  </required_header>
  <id_info>
    <org_study_id>1608039</org_study_id>
    <secondary_id>2017-A00408-45</secondary_id>
    <nct_id>NCT03355781</nct_id>
  </id_info>
  <brief_title>Childhood Trauma in Schizophrenia: Exploration of Links Between Gene Expression, Cerebral Morphology and Symptomatology</brief_title>
  <acronym>SCHIZO'TRAUMA</acronym>
  <official_title>Childhood Trauma in Schizophrenia: Exploration of Links Between Gene Expression, Cerebral Morphology and Symptomatology. SCHIZO' TRAUMA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Saint Etienne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Saint Etienne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Childhood trauma is known as a vulnerability factor in schizophrenia. In healthy volunteers,&#xD;
      these adversities are linked to a decrease of grey matter of the brain, similar to those&#xD;
      observed in schizophrenia.&#xD;
&#xD;
      In a previous study based on Voxel-Based Morphometry (VBM), including 21 schizophrenic&#xD;
      patients and 30 healthy volunteers, the investigators shown a negative correlation between&#xD;
      emotional neglect (important dimension in childhood trauma) and grey matter decrease. This&#xD;
      strong correlation was significantly higher in schizophrenic patients than in healthy&#xD;
      volunteers, suggesting a higher genetic predisposition to environmental factors in&#xD;
      schizophrenic people.&#xD;
&#xD;
      Currently, interaction between genetic predisposition and environmental stress factors is the&#xD;
      major model for understanding in schizophrenia. In order to analyze both effects on human&#xD;
      body, particularly on brain, several studies currently focus on the product of genetic&#xD;
      expression, the ribonucleic acid (ARN).&#xD;
&#xD;
      The purpose of this study is to provide an explanatory model of links between childhood&#xD;
      trauma, candidate gene for schizophrenia expression, cerebral morphology and schizophrenic&#xD;
      symptomatology. Using conceptual framework of stress vulnerability, structural equation&#xD;
      modeling (SEM) will allow testing causal link between these different variables.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 14, 2018</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Childhood Trauma Questionnaire (CTQ) for childhood trauma.</measure>
    <time_frame>5 days</time_frame>
    <description>development of an etiopathogenic model characteristic of schizophrenia&#xD;
Childhood Trauma Questionnaire : to assess five types of childhood trauma :&#xD;
Emotional neglect&#xD;
physical abuse&#xD;
emotional abuse&#xD;
physical neglect&#xD;
sexual abuse&#xD;
Each item being rated in 5 answer choice from 1 to 5 (never, rarely, sometimes, often or very often)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quantitative measurement of RNAs</measure>
    <time_frame>5 days</time_frame>
    <description>development of an etiopathogenic model characteristic of schizophrenia</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Voxel-based morphometry (VBM) for total gray matter</measure>
    <time_frame>5 days</time_frame>
    <description>development of an etiopathogenic model characteristic of schizophrenia</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Voxel-based morphometry (VBM) for regional gray matter density.</measure>
    <time_frame>5 days</time_frame>
    <description>development of an etiopathogenic model characteristic of schizophrenia</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Connectivity in the cortico-limbic circuit</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volumetry of the brain</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of BOLD activity in the cortico-limbic circuit in patients with patients with symptomatic variables</measure>
    <time_frame>5 days</time_frame>
    <description>symptomatic variables : PANSS scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of BOLD activity in the cortico-limbic circuit with emotional variables</measure>
    <time_frame>5 days</time_frame>
    <description>emotional variables : ERS scale, ERQ scale, TAS-20 scale, SAS scale, AES-C scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of BOLD activity in the cortico-limbic circuit with personality characteristics</measure>
    <time_frame>5 days</time_frame>
    <description>personality characteristics : EPQ-R scale, SPQ scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of BOLD activity in the cortico-limbic circuit with history of trauma in childhood</measure>
    <time_frame>5 days</time_frame>
    <description>history of trauma in childhood : CTQ scale</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Schizophrenic patients</arm_group_label>
    <description>Patients will have clinical psychiatric evaluation, brain imaging and blood sample</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Related volunteers (first degree relative of patient)</arm_group_label>
    <description>Related volunteers will have clinical psychiatric evaluation, brain imaging and blood sample</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <description>Healthy volunteers will have clinical psychiatric evaluation, brain imaging and blood sample</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>magnetic resonance imaging (MRI)</intervention_name>
    <description>brain imaging : structural anatomy, emotional congruence, anatomic connectivity, functional connectivity</description>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <arm_group_label>Related volunteers (first degree relative of patient)</arm_group_label>
    <arm_group_label>Schizophrenic patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood sample</intervention_name>
    <description>27,5 ml of blood sample : genetic analysis and biobank</description>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <arm_group_label>Related volunteers (first degree relative of patient)</arm_group_label>
    <arm_group_label>Schizophrenic patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Clinical psychiatric evaluation</intervention_name>
    <description>Global Assessment Scale(GAS),Mini International Neuropsychiatric Interview(MINI),Positive and Negative Symptoms Scale(PANSS),Family Interview for Genetic Studies(FIGS),Calgary Depression Scale for Schizophrenia(CDSS),extrapyramidal side effects evaluation or Simpson-Angus scale evaluation(ESRS),Apathy Evaluation Scale(AES-C),State-Trait Anxiety Inventory(STAI),Beck Depression Inventory(BDI-13),Eysenck Personality Questionnaire-Revised(EPQ-R),Assessment of Schizotypal Personality(SPQ),Emotion Regulation Questionnaire(ERQ),Emotional Reactivity Scale(ERS),Toronto Alexithymia Scale(TAS-20),social anhedonia scale(SAS),Childhood Trauma Questionnaire(CTQ),Clinical-administered Post Traumatic Stress Disorder Scale(CAPS),Wechsler Adult Intelligence Scale(WAIS-III),Trail Making Test(TMT),Pen and paper visuospatial working memory(DOT-test),impulsivity test(GoStop),Stroop test,National Adult Reading Test(NART),Wechsler Adult Intelligence Scale(WAIS-III),Facial Emotion Recognition task(FER)</description>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <arm_group_label>Related volunteers (first degree relative of patient)</arm_group_label>
    <arm_group_label>Schizophrenic patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Schizophrenic patients, related volunteers (first degree relative of patient) and healthy&#xD;
        volunteers&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria of patients :&#xD;
&#xD;
          -  For women with reproductively active age period: suitable contraceptive method and&#xD;
             negative pregnancy test&#xD;
&#xD;
          -  Schizophrenia diagnosis (according to DSM 5)&#xD;
&#xD;
          -  Regular follow-up care at hospital&#xD;
&#xD;
          -  No change in antipsychotic medication (medication AND dosage) within at least six&#xD;
             weeks&#xD;
&#xD;
          -  Patient into remission : constant dosage, out-patient and meeting Andreassen criteria&#xD;
&#xD;
          -  Who have given their informed consent before participating in the study.&#xD;
&#xD;
          -  Physical examination without significant clinical physical anomaly&#xD;
&#xD;
          -  No serious somatic pathology&#xD;
&#xD;
          -  Affiliates or entitled to a social security scheme&#xD;
&#xD;
        Exclusion Criteria of patients :&#xD;
&#xD;
          -  For women with reproductively active age period: no suitable contraceptive method&#xD;
             (oral, hormonal, intramuscular, intrauterine device, or surgical)&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
&#xD;
          -  Not meeting schizophrenic criteria according to DSM 5 or presenting resistant&#xD;
             schizophrenic criteria according Kane criteria&#xD;
&#xD;
          -  Presenting a serious somatic disorder or neurological (particularly Parkinson disease,&#xD;
             epilepsy, tardive dyskinesia)&#xD;
&#xD;
          -  Cardiovascular, hepatic or serious renal diseases&#xD;
&#xD;
          -  Contraindication to MRI examination, particularly ocular or intracranial metallic&#xD;
             foreign object,pacemaker, artificial heart valve, surgical clip&#xD;
&#xD;
          -  Claustrophobia, significant tatoo in the high part of the body, IUD incompatible with&#xD;
             MRI 3Tesla&#xD;
&#xD;
          -  Alcohol or drug addiction, within the last year&#xD;
&#xD;
          -  Recruited in other clinical trial or exclusion period from previous trial.&#xD;
&#xD;
          -  Susceptibility to self-harm behaviour according to investigator&#xD;
&#xD;
        Inclusion Criteria of Related volunteers :&#xD;
&#xD;
          -  Age, gender and socio-educational level similar to recruited patients&#xD;
&#xD;
          -  Who have given their informed consent before participating in the study.&#xD;
&#xD;
          -  First degree relative of schizophrenic patient diagnosed according DSM IV criteria&#xD;
&#xD;
          -  No schizophrenia diagnosis according DSM IV criteria&#xD;
&#xD;
          -  No psychiatric history and free of psychotropic drugs/treatment&#xD;
&#xD;
          -  Physical examination without significant clinical anomaly&#xD;
&#xD;
          -  Affiliates or entitled to a social security scheme&#xD;
&#xD;
        Exclusion Criteria of Related volunteers :&#xD;
&#xD;
          -  For women with reproductively active age period: no suitable contraceptive method&#xD;
             (oral, hormonal, intramuscular, intrauterine device, or surgical)&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
&#xD;
          -  Presenting somatic, neurological or psychiatric disorder&#xD;
&#xD;
          -  Alcohol or drug addiction, within the last year&#xD;
&#xD;
          -  Recruited in other clinical trial or exclusion period from previous trial.&#xD;
&#xD;
          -  Contraindication to MRI examination, particularly ocular or intracranial metallic&#xD;
             foreign object, pacemaker, artificial heart valve, surgical clip&#xD;
&#xD;
          -  Claustrophobia, significant tatoo in the high part of the body, IUD incompatible with&#xD;
             MRI 3Tesla&#xD;
&#xD;
        Inclusion Criteria of Healthy volunteers :&#xD;
&#xD;
          -  Age, gender and socio-educational level similar to recruited patients&#xD;
&#xD;
          -  Who have given their informed consent before participating in the study.&#xD;
&#xD;
          -  No schizophrenia diagnosis according DSM IV criteria&#xD;
&#xD;
          -  No personal or family history of psychiatric disorders&#xD;
&#xD;
          -  Free of psychotropic drugs/treatment&#xD;
&#xD;
          -  Physical examination without significant clinical anomaly&#xD;
&#xD;
          -  Affiliates or entitled to a social security scheme&#xD;
&#xD;
        Exclusion Criteria of Healthy volunteers :&#xD;
&#xD;
        Beside the absence of schizophrenia diagnosis, healthy volunteers should meet the same&#xD;
        exclusion criteria as patients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Samy DALLEL, MD</last_name>
    <phone>0477828720</phone>
    <phone_ext>+33</phone_ext>
    <email>samy.dallel@chu-st-etienne.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marie PEURIERE</last_name>
    <phone>(0)477829272</phone>
    <phone_ext>33</phone_ext>
    <email>marie.peuriere@chu-st-etienne.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU de Saint Etienne</name>
      <address>
        <city>Saint-Étienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samy DALLEL, MD</last_name>
      <phone>0477828720</phone>
      <phone_ext>+33</phone_ext>
      <email>samy.dallel@chu-st-etienne.fr</email>
    </contact>
    <investigator>
      <last_name>Eric FAKRA, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Claire BOUTET, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>November 10, 2017</study_first_submitted>
  <study_first_submitted_qc>November 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 28, 2017</study_first_posted>
  <last_update_submitted>January 15, 2021</last_update_submitted>
  <last_update_submitted_qc>January 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>childhood trauma</keyword>
  <keyword>candidate gene expression</keyword>
  <keyword>cerebral morphology</keyword>
  <keyword>schizophrenic symptomatology</keyword>
  <keyword>conceptual framework of stress vulnerability</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

